Fresenius Kabi is further expanding its Austrian facilities. The company will invest more than €60 million through 2023 to expand capacity and upgrade infrastructure at its production plant in Graz and packaging center in nearby Werndorf. The measures will be focused on the freeze-drying area and the lines for filling and packing glass bottles and ready-to-administer prefilled syringes.
“Prefilled syringes are a fast-growing market for us,” said Plant Manager Dr. Ruth Staubmann. “Many healthcare institutions and organizations recognize the clear advantages in terms of their rapid application and, above all, safety of use.” The expansion of the Graz plant will approximately double production capacity in this product category.
Fresenius Kabi produces liquid pharmaceuticals and clinical nutrition products for the Austrian and international markets in Graz. The site has special expertise in aseptic production and the manufacturing of complex products such as anesthetics, analgesics, anti-infectives and antibiotics. It also makes clinical nutrition products. In total, Fresenius Kabi currently has more than 900 employees in Graz. The number of additional jobs that will be created through the expansion cannot yet be determined.
In addition to the Graz plant and the packaging and logistics center in Werndorf, Fresenius Kabi’s Austrian operations include a research and development center in Grambach and a plant and distribution facility in Linz that specializes in the production of active ingredients and lactulose. The company employs a total of about 1,500 people in Austria.